Victory Capital Management Inc. purchased a new position in Mersana Therapeutics, Inc. (NASDAQ:MRSN) during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm purchased 54,000 shares of the company’s stock, valued at approximately $754,000. Victory Capital Management Inc. owned about 0.24% of Mersana Therapeutics at the end of the most recent reporting period.

Separately, DekaBank Deutsche Girozentrale acquired a new stake in Mersana Therapeutics in the 2nd quarter worth $676,000. 74.64% of the stock is owned by hedge funds and other institutional investors.

In other Mersana Therapeutics news, major shareholder M James Barrett purchased 1,000,000 shares of the firm’s stock in a transaction that occurred on Monday, July 3rd. The shares were acquired at an average cost of $15.00 per share, for a total transaction of $15,000,000.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN) opened at 16.20 on Friday. The firm’s market capitalization is $367.95 million. The stock’s 50 day moving average is $16.19 and its 200 day moving average is $15.41. Mersana Therapeutics, Inc. has a 12 month low of $12.71 and a 12 month high of $18.48.

Mersana Therapeutics (NASDAQ:MRSN) last issued its quarterly earnings data on Friday, August 11th. The company reported ($6.33) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.56) by ($5.77). The firm had revenue of $3.73 million for the quarter, compared to the consensus estimate of $3.33 million. Equities research analysts forecast that Mersana Therapeutics, Inc. will post ($6.59) earnings per share for the current fiscal year.

Several analysts have issued reports on MRSN shares. Wedbush restated an “outperform” rating and issued a $25.00 price target on shares of Mersana Therapeutics in a research report on Monday, July 24th. J P Morgan Chase & Co started coverage on shares of Mersana Therapeutics in a research report on Monday, July 24th. They issued an “overweight” rating and a $23.00 price target on the stock. Cowen and Company started coverage on shares of Mersana Therapeutics in a research report on Monday, July 24th. They issued an “outperform” rating on the stock. Finally, Leerink Swann started coverage on shares of Mersana Therapeutics in a research report on Monday, July 24th. They issued an “outperform” rating and a $23.00 price target on the stock.

TRADEMARK VIOLATION WARNING: This report was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another domain, it was stolen and reposted in violation of U.S. & international copyright legislation. The legal version of this report can be read at https://www.thecerbatgem.com/2017/09/17/victory-capital-management-inc-buys-shares-of-54000-mersana-therapeutics-inc-mrsn.html.

About Mersana Therapeutics

Mersana Therapeutics, Inc is a United States-based biotechnology company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs). The Company focuses on advancing a pipeline of targeted oncology therapeutics leveraging its Fleximer immunoconjugate technology. The Fleximer platform allows it to design ADCs with specific properties and manage the drug’s chances of attacking cancers.

Institutional Ownership by Quarter for Mersana Therapeutics (NASDAQ:MRSN)

Receive News & Stock Ratings for Mersana Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mersana Therapeutics Inc. and related stocks with our FREE daily email newsletter.